These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1439626)

  • 1. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
    Knill-Jones RP
    Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic consequences of NSAID-induced gastropathy: the French context.
    de Pouvourville G
    Scand J Rheumatol Suppl; 1992; 96():49-53. PubMed ID: 1439624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic consequences of NSAID-induced gastrointestinal damage.
    de Pouvourville G; Tasch RF
    Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
    Goldstein JL; Larson LR; Yamashita BD
    Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
    Al MJ; Michel BC; Rutten FF
    Pharmacoeconomics; 1996 Aug; 10(2):141-51. PubMed ID: 10163417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.
    Plosker GL; Lamb HM
    Pharmacoeconomics; 1999 Jul; 16(1):85-98. PubMed ID: 10539124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
    Al MJ; Maniadakis N; Grijseels EW; Janssen M
    Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada.
    Sclar DA; Robison LM; Maheu A; Skaer TL
    J Int Med Res; 1995; 23(6):439-48. PubMed ID: 8746611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
    Kristiansen IS; Kvien TK; Nord E
    Arthritis Rheum; 1999 Nov; 42(11):2293-302. PubMed ID: 10555023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
    Bach GL
    Scand J Rheumatol Suppl; 1992; 96():5-6. PubMed ID: 1439625
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
    Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
    Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.
    Davis R; Yarker YE; Goa KL
    Drugs Aging; 1995 Nov; 7(5):372-93. PubMed ID: 8573992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
    Liaropoulos L
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():39-46. PubMed ID: 10369405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
    Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J
    Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
    Soto Alvarez J
    An Med Interna; 2000 Sep; 17(9):477-84. PubMed ID: 11100534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients.
    Stupnicki T; Dietrich K; González-Carro P; Straszak A; Terjung A; Thomas KB; Lühmann R; Fischer R
    Digestion; 2003; 68(4):198-208. PubMed ID: 14707396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.
    van Dieten HE; Korthals-de Bos IB; van Tulder MW; Lems WF; Dijkmans BA; Boers M
    Ann Rheum Dis; 2000 Oct; 59(10):753-9. PubMed ID: 11005773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland.
    Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD
    Digestion; 2004; 69(1):10-9. PubMed ID: 14755148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.
    Morant SV; Shield MJ; Davey PG; MacDonald TM
    Pharmacoepidemiol Drug Saf; 2002; 11(5):393-400. PubMed ID: 12271881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.